H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $120 from $110 and keeps a Buy rating on the shares after the company announced a new $40,000 list price for Tryngolza. The firm is updating its peak sales estimate to $4.5B in 2036, up from $4.2B previously, noting that its new peak sales estimate is based on the established $40,000 wholesale acquisition cost translating to roughly $28,000 on a net price basis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis announces NDA for zilganersen accepted by U.S. FDA for Priority Review
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
- Ionis Pharmaceuticals Announces Board Retirements and New Appointment
- Ionis Pharmaceuticals price target raised to $100 from $87 at Piper Sandler
- Ionis Pharmaceuticals announces olezarsen sNDA accepted for FDA priority review